Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
It is used as an expectorant, alone or in association with other products. Proofs on its effectiveness are sparse (Smith 2014, Reis 2010, Bolser 2006). In some instances, preparations of Guaifenesin may contain alcohol as excipient with a concentration as high as 5%. Oral administration every 4 to 6 hours.
At latest update, relevant published data on excretion into breast milk were not found.
Until more information on this medication is available, other option known to be safer would be recommended, mostly in the post-natal period or in cases of prematurity.
If used while breastfeeding, a moderate use with the lowest dose as possible and avoiding those preparations with alcoholic excipient, should be preferred.
Because effectiveness is poor and likelihood of side effects does exist, especially in multi-association, the US Agency for Drug Administration (FDA) is currently doing efforts for discontinuation of this and others at-the-counter products, that are formulated for cough relief: Guaifenesin, Dextromethorphan, Phenylephrine, Pseudoephedrine, Brompheniramine, etc. (FDA 2015)